Search results
Results from the WOW.Com Content Network
Like the cells of atypical lobular hyperplasia and invasive lobular carcinoma, the abnormal cells of LCIS consist of small cells with oval or round nuclei and small nucleoli detached from each other. [12] Mucin-containing signet-ring cells are commonly seen. LCIS generally leaves the underlying architecture intact and recognisable as lobules.
The National Comprehensive Cancer Network (NCCN) is an alliance of 33 [1] cancer centers in the United States, most of which are designated by the National Cancer Institute (one of the U.S. National Institutes of Health) as comprehensive cancer centers. It is a non-profit organization with offices in Plymouth Meeting, Pennsylvania.
Atypical hyperplasia is a high-risk premalignant lesion of the breast. It is believed that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade mammary ductal carcinoma , whereas atypical lobular hyperplasia (ALH) serves as a risk indicator.
Carcinomas of mixed type will have a specialized pattern or lobular carcinoma in the majority (i.e. at least 50%) of the tumor and a non-specialized pattern in between 10 and 49% of the sample. Thus, such tumors will be called mixed invasive NST and special type or mixed invasive carcinoma NST and lobular carcinoma. [24]
A treatment guide provided by NCCN Guidelines for Patients is available, [16] while the NCCN Clinical Practice Guidelines in Oncology provides a reference for clinicians. [17] Any proposed therapeutic strategy must have minimal acute and long-term toxicities. [15]
Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [1] It accounts for 5–10% of invasive breast cancer . [ 2 ] [ 3 ] Rare cases of this carcinoma have been diagnosed in men (see male breast cancer ).
The American National Comprehensive Cancer Network's official guidelines list TTFields as an option for the treatment of recurrent glioblastoma, but note substantial disagreement among the members of the expert panel making this recommendation. [2] High-quality evidence for the efficacy of TTFields in oncology is limited.
Based upon the work of the international AGREE Collaboration for the quality of clinical practice guidelines, [3] an organised network for organisations and experts working in the field of evidence-based guidelines was proposed in early 2002 at the first international guideline conference in Berlin, Germany. [4]